Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: moby_dick who wrote (10794)	2/11/1999 7:28:00 PM
From: moby_dick	Read Replies (1) \| Respond to of 122088

Here's another <ENMD> with a different spin from MSNBC: ‘We are excited about this.' — DR. JAMES PLUDA National Cancer Institute THIS MAKES CANCER fall dormant or disappear altogether in lab animals. But no one knows if the same thing will happen in people. The two proteins have been the subject of a roller coaster of speculation ever since an enthusiastic front-page story in The New York Times last May on Dr. Judah Folkman and his experiments. But doubts grew last fall when it was reported that scientists from the National Cancer Institute in Frederick, Md., had not been able to reproduce Folkman's results. This week, an NCI team said it had at last duplicated Folkman's work. The breakthrough using endostatin came only when the NCI scientists conducted the experiments at Folkman's laboratory at Children's Hospital in Boston. HUMAN STUDIES IN DESIGN On Thursday, another team of NCI researchers said it has begun designing endostatin studies in humans. The NCI wants to test the drug for safety in perhaps 10 to 30 patients with tumors of the breast, kidney, skin or other parts of the body. “We are excited about this,” said Dr. James Pluda, an NCI senior drug investigator. “If all goes well, we hope to begin by the third quarter of this year and earlier, if possible.” Pluda said it will take about six months to design the study before it can be submitted to the Food and Drug Administration for approval. Endostatin and angiostatin are being developed by EntreMed Inc., a small biotech company in Rockville, Md., whose stock price has risen and plunged with each bit of news about the drugs. On Thursday, it said it is scaling up production of endostatin and will have enough for the preliminary human testing proposed by the NCI. In recent months, NCI scientists in Frederick attempted without success to duplicate Folkman's work using endostatin shipped to them by his lab. The researchers assumed that technical problems, including possible trouble transporting the fragile protein, messed up their experiments. They traveled to Folkman's lab, where last month they finally succeeded in using the protein to shrink mouse tumors. In a statement Thursday, the hospital hinted that the problem might have involved the proper way to inject mice with endostatin. Next, Children's scientists will go to Frederick to help the NCI duplicate the experiments there. At least one other scientific team has independently published a report of similar success with endostatin, and the hospital said several others are nearing publication. EntreMed is developing endostatin alone. It had a joint venture with Bristol-Myers Squibb Co. to make angiostatin, but Bristol-Myers announced this week that it is pulling out because of difficulty producing reliable quantities of the protein. EntreMed's shares lost half their value on Wednesday but bounced back on Thursday. The NCI scientists' success in duplicating Folkman's work was first reported by The Boston Globe on Thursday. EntreMed spokeswoman Mary P. Sundeen said the company is confident it will be able to develop angiostatin alone. She said Entremed hopes to begin human studies of the protein late this year. © 1999 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

To: moby_dick who wrote (10794)	2/11/1999 8:10:00 PM
From: surelock	Read Replies (2) \| Respond to of 122088

I've learned a ton from Anthony, and all the other great traders on this thread, but the most valuable lesson has been in the area of money management. I have a short position in ENMD, and hope it goes up in the morning. Reason is, I start with 25 or 50% of a position. If I am early, I add more on a gap higher. If it goes down, I have a partial position, and the worst thing that happens is that it goes down, and I never get the full position, as happened with SATH. In fact, chances are that most of the time I will not get to a 100% position. That way, I'm never on the ropes. Small price to pay, allows you to sleep well at night, and save room for other opportunities that pop up. SH